Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight

Dow Jones

05 Nov 2024

By Sabela Ojea

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

The genetic testing and precision medicine company on Monday said it strongly disagrees with UnitedHealthcare's inclusion of GeneSight after it announced it would no longer cover multi-panel genetic tests for behavioral-health diagnoses.

"Myriad is actively engaging with UnitedHealthcare to discuss the large body of evidence for Myriad's proprietary and clinically differentiated mental health medication test," the company said.

Myriad Genetics doesn't believe that the updated policy affects coverage of GeneSight by UnitedHealthcare under Medicare Advantage and managed Medicaid plans, it added.

The company is expected to post third-quarter results after the market close Thursday.

Myriad Genetics shares were down 4.9% at $16.93 in morning trading. The stock has dropped 34% over the past three months.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

November 04, 2024 11:38 ET (16:38 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2481536976"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2481536976\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2481536976?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-05 00:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481536976","market":"sg","top_or_hot":-1,"title":"Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy. \n</p>\n<p>\n  The genetic testing and precision medicine company on Monday said it strongly disagrees with UnitedHealthcare's inclusion of GeneSight after it announced it would no longer cover multi-panel genetic tests for behavioral-health diagnoses. \n</p>\n<p>\n  \"Myriad is actively engaging with UnitedHealthcare to discuss the large body of evidence for Myriad's proprietary and clinically differentiated mental health medication test,\" the company said. \n</p>\n<p>\n  Myriad Genetics doesn't believe that the updated policy affects coverage of GeneSight by UnitedHealthcare under Medicare Advantage and managed Medicaid plans, it added. \n</p>\n<p>\n  The company is expected to post third-quarter results after the market close Thursday. \n</p>\n<p>\n  Myriad Genetics shares were down 4.9% at $16.93 in morning trading. The stock has dropped 34% over the past three months. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 04, 2024 11:38 ET (16:38 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMyriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-05 00:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy. \n</p>\n<p>\n  The genetic testing and precision medicine company on Monday said it strongly disagrees with UnitedHealthcare's inclusion of GeneSight after it announced it would no longer cover multi-panel genetic tests for behavioral-health diagnoses. \n</p>\n<p>\n  \"Myriad is actively engaging with UnitedHealthcare to discuss the large body of evidence for Myriad's proprietary and clinically differentiated mental health medication test,\" the company said. \n</p>\n<p>\n  Myriad Genetics doesn't believe that the updated policy affects coverage of GeneSight by UnitedHealthcare under Medicare Advantage and managed Medicaid plans, it added. \n</p>\n<p>\n  The company is expected to post third-quarter results after the market close Thursday. \n</p>\n<p>\n  Myriad Genetics shares were down 4.9% at $16.93 in morning trading. The stock has dropped 34% over the past three months. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 04, 2024 11:38 ET (16:38 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03650","symbol_name":"KEEP","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2481536976","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481536976","pubTimestamp":1730738280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.The genetic testing and precision medicine company on Monday said it strongly disagrees with UnitedHealthcare's inclusion of GeneSight after it announced it would no longer cover multi-panel genetic tests for behavioral-health diagnoses.\"Myriad is actively engaging with UnitedHealthcare to discuss the large body of evidence for Myriad's proprietary and clinically differentiated mental health medication test,\" the company said.Myriad Genetics doesn't believe that the updated policy affects coverage of GeneSight by UnitedHealthcare under Medicare Advantage and managed Medicaid plans, it added.The company is expected to post third-quarter results after the market close Thursday.Myriad Genetics shares were down 4.9% at $16.93 in morning trading. The stock has dropped 34% over the past three mo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03650":"KEEP","BK4139":"生物科技","MYGN":"万基遗传","BK1215":"特殊消费者服务"},"translate_title":"Myriad Genetics正在与UnitedHealthcare积极谈判，以保持GeneSight的覆盖范围","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03650":1,"MYGN":1},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy. \n\n\n  The genetic testing and precision medicine company on Monday said it strongly disagrees with UnitedHealthcare's inclusion of GeneSight after it announced it would no longer cover multi-panel genetic tests for behavioral-health diagnoses. \n\n\n  \"Myriad is actively engaging with UnitedHealthcare to discuss the large body of evidence for Myriad's proprietary and clinically differentiated mental health medication test,\" the company said. \n\n\n  Myriad Genetics doesn't believe that the updated policy affects coverage of GeneSight by UnitedHealthcare under Medicare Advantage and managed Medicaid plans, it added. \n\n\n  The company is expected to post third-quarter results after the market close Thursday. \n\n\n  Myriad Genetics shares were down 4.9% at $16.93 in morning trading. The stock has dropped 34% over the past three months. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 04, 2024 11:38 ET (16:38 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}